New report heralds a revolution in cancer R&D trends - and the sticker shock that comes with it
There’s a revolution playing out in cancer R&D.
Over the last decade drug developers focused on oncology have teamed with regulators on designing a shorter R&D path for new cancer drugs, using trial designs that have sped clinical work and slashed the number of patients needed to demonstrate safety and efficacy.
With the number of new checkpoint combos in the clinic escalating rapidly, the late-stage pipeline of new cancer drugs has exploded, growing 7.7% in just the last year to 631 new molecules. The two initial PD-1 approvals of Opdivo and Keytruda alone spawned 135 combination studies. And the work overall is changing the standard of care in the field — at a high cost for the payers footing the bill.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.